Redeye updates its forecast and valuation following Modelon’s Q2 2025 report, which came broadly in ...
Soft Q2, but heading in the right direction We forecast Q2 sales of EUR 27.
W&E headwinds had a greater impact than we anticipated in Q2, resulting in net sales coming in sligh...
India returns to growth and margins expand Medicover delivered another strong quarter, beating adj.
Safello has announced a partnership with Marginalen Bank, positioning itself as the first crypto bro...
Stronger order intake, but lower sales Cavotec reported order intake of EUR 44m (+7% vs.
Redeye notes that Gapwaves' Q2 2025 report exceeded its estimates on all key metrics.
Net sales and clean EBIT were below market consensus (LSEG) in Q2.
Redeye updates its estimates and valuation following MedCap’s Q2 2025 report.
Redeye comments on Polygiene Group´s Q2 2025. Polygiene Group delivered negative growth of -12% y/y.
Sales and EBIT miss of SEK 22m and 7m vs. ABGSCe This afternoon, Energy Save issued a profit warning...
Physitrack’s Q2 2025 results came in broadly in line with our expectations.
Redeye shares its initial view on Modelon’s Q2 2025 report.
Prisma redovisade en stark Q2 med 15,5 % högre intäkter och ett förvaltningsresultat på 48 Mkr (11).
Hanza levererade ett starkt Q2 med 3 % organisk tillväxt och rörelseresultat på 97 Mkr, i linje med ...
Redeye returns with a more in-depth take on the Q2 report.
Bright spot in FMWT Q2 sales were SEK 228m, -3% y-o-y and flat y-o-y in local currencies, while EBIT...
Q2 yet another miss As feared, Invisio faced tough comps in Q2 and missed expectations across most k...
Q2 results Sales fell 3% y-o-y and were 7% below our estimate.
Redeye leaves an initial comment on the strong Q2 report, where OPEX cuts and higher distributor sal...